ASTER 70s Trial: Key Details and Patient selection

The ASTER 70s trial investigated the benefits of chemotherapy in older women with high-risk, hormone receptor-positive breast cancer. This trial has prompted discussion, and clarifying its specific parameters is crucial for accurate interpretation.

The study focused on women aged 70 years and older who had already undergone surgery for breast cancer. Specifically, the cancer had too be estrogen receptor-positive (ER+), HER2-negative, and classified as high-risk based on a high genomic grade index (GGI). The GGI is a tool used to assess the aggressiveness of the tumor.

Patients meeting these criteria were randomly assigned to one of two treatment groups. One group received chemotherapy followed by hormonotherapy, while the other received hormonotherapy alone. This randomized approach aimed to determine if adding chemotherapy improved outcomes for this specific patient population.

It’s important to note the strict inclusion criteria. The trial didn’t include all women over 70 with breast cancer; it targeted a subset defined by tumor characteristics and risk assessment. This focused approach allows for a more precise evaluation of chemotherapy’s role in a high-risk group.

Understanding these details is essential when considering the trial’s implications for broader clinical practice. The ASTER 70s trial provides valuable data, but its findings apply most directly to women matching the specific characteristics of the study participants.